Search
for

    Glossary Ozempic

    Ozempic is a medication primarily used to manage type 2 diabetes by mimicking the effects of the hormone GLP-1, which helps regulate blood sugar levels. Its relevance to hair loss stems from anecdotal reports and emerging studies suggesting that weight loss associated with Ozempic may lead to temporary hair shedding in some individuals. Key distinguishing characteristics include its active ingredient, semaglutide, and its mechanism of action, which involves appetite suppression and increased insulin sensitivity. While not directly a hair loss treatment, its side effects can impact hair health in certain users.

    Sort by

    Research 30 of 37

    1. Skin Impacts and Tradeoffs of GLP-1 Therapy: Improved Patient-Reported Outcomes of Inflammatory Skin Disease in the Era of “Ozempic Face” Dermatology and Therapy · 2026
    2. GLP-1 e Estética: Ozempic Face, Flacidez e Recuperação Open MIND · 2026
    3. GLP-1 Receptor Agonists: Beyond Their Pancreatic Effects Frontiers in Endocrinology · 2021 · 59 citations
    4. Semaglutide Treatment of Excessive Body Weight in Obese PCOS Patients Unresponsive to Lifestyle Programs Journal of Clinical Medicine · 2023 · 29 citations
    5. Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study Cardiovascular Drugs and Therapy · 2024 · 25 citations
    6. Alopecia and Semaglutide: Connecting the Dots for Patient Safety Journal of Cosmetic Dermatology · 2025 · 4 citations
    7. Targeting Obesity in PCOS: A Review of Current Pharmacological Interventions and Future Directions Medicina Moderna - Modern Medicine · 2025 · 1 citations
    8. Nonscarring Alopecia in Adults Treated With GLP ‐1s: A Propensity Score Matched TriNetX Cohort Study The Laryngoscope · 2026
    9. EFLÚVIO TELÓGENO ASSOCIADO AO USO DE MEDICAMENTOS EMAGRECEDORES: MECANISMOS FISIOPATOLÓGICOS E EVIDÊNCIAS CLÍNICAS Revista Ibero-Americana de Humanidades, Ciências e Educação · 2026
    10. 0439 Temporal–phenotype signatures of alopecia associated with GLP-1–based therapies: A PRISMA-ScR scoping review Journal of Investigative Dermatology · 2026
    11. 76708 Risk of Developing Scarring and Non-Scarring Alopecia with GLP-1 and GLP-1/GIP Agonist Utilization Journal of the American Academy of Dermatology · 2026
    12. Mitigating GLP-1–Related Dermatologic Adverse Effects through Methylene Blue’s Antioxidant Action Annals of Clinical Pathology · 2026
    13. Hair Loss in Patients on Glucagon-Like Peptide 1 Receptor Agonists: Understanding Risks and Managing Outcomes Dermatology and Therapy · 2026
    14. Incretin-Based Drugs for Obesity: Common and Drug-Specific Reporting Patterns of Adverse Drug Reactions—A Comparative Disproportionality Analysis Using EudraVigilance Reports Integrating SmPC Data Pharmaceuticals · 2026
    15. Effects of Glucagon-like Peptide-1 Receptor Agonists on Skin Homeostasis and Skin Aging Processes Journal of Clinical Medicine · 2026
    16. GLP-1 therapies and hair loss: A systematic review of current evidence and implications for counseling Science Progress · 2026
    17. Semaglutide-Induced Atypical Pustular Drug Eruption: A Case Report Cureus · 2026
    18. Telogen Effluvium and Metabolic Stress in Modern Weight Loss Interventions: A Narrative Clinical Review Brazilian Journal of Hair Health · 2025
    19. Dermatologic Implications of GLP-1 Receptor Agonist Medications: A Comprehensive Review Skin Appendage Disorders · 2025
    20. Abstract 4142154: Risk of Suicide, Hair Loss, and Aspiration with Glucagon-like Peptide 1 Receptor Agonists: A Real-World Pharmacovigilance Study from the FAERS database Circulation · 2024
    21. 53028 Semaglutide and Hair Loss: A Real-World Analysis Journal of the American Academy of Dermatology · 2024
    22. GLP-1 RAs and Skin Health: Exploring Dermatologic Side Effects and Therapeutic Interventions 2025
    23. Benefit-Risk Assessment of GLP-1 Receptor Agonists: Implications for Dermatologists and Plastic Surgeons Dermatology and Therapy · 2025 · 1 citations
    24. Endocrinologia e Medicina Estética Ed. X Editora Pasteur eBooks · 2026
    25. Semaglutide and the Skin: An Overview of Current Evidence Quality in Sport · 2026
    26. Holistic management plan for polycystic ovarian syndrome (PCOS): A systematic literature review International Journal of Clinical Obstetrics and Gynaecology · 2025
    27. Exploring Herbal Alternatives to Pharmaceutical Treatments for Polycystic Ovary Syndrome 2025
    28. Farmácia da Cruz, Porto e Serviços Farmacêuticos do Hospital General Universitario Gregorio Marañón, Espanha Open Repository of the University of Porto (University of Porto) · 2024
    29. New-Onset Alopecia Is Significantly Higher with Tirzepatide than with Semaglutide, Even After Weight-Loss Matching Preprints.org · 2026
    30. Dermatological adverse reactions and therapeutic potential of semaglutide, liraglutide and tirzepatide: Analysis of UK pharmacovigilance data and literature review 2025 · 1 citations